The NCCN Guidelines indicate rusfertide for patients regardless of risk status for patients who are intolerant to phlebotomy or receive frequent phlebotomy.

Community oncology practices rapidly adopt bispecific therapy, but reimbursement gaps, intensive monitoring demands, and limited hospital coordination hinder safe, scalable in-office programs.

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.

The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.

Real-world ESAS data show higher symptom burden after cancer diagnosis shifts spending from treatment to ER, home and mental health care.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.